S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Stock market today: Asian world shares mostly lower after Wall St has its worst week in 6 months
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
Writers Guild and Hollywood studios reach tentative agreement to end strike. No deal yet for actors
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Canadian autoworkers ratify new labor agreement with Ford
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Stock market today: Asian world shares mostly lower after Wall St has its worst week in 6 months
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
Writers Guild and Hollywood studios reach tentative agreement to end strike. No deal yet for actors
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Canadian autoworkers ratify new labor agreement with Ford
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Stock market today: Asian world shares mostly lower after Wall St has its worst week in 6 months
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
Writers Guild and Hollywood studios reach tentative agreement to end strike. No deal yet for actors
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Canadian autoworkers ratify new labor agreement with Ford
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Stock market today: Asian world shares mostly lower after Wall St has its worst week in 6 months
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
Writers Guild and Hollywood studios reach tentative agreement to end strike. No deal yet for actors
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Canadian autoworkers ratify new labor agreement with Ford
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
NASDAQ:RGNX

REGENXBIO (RGNX) Competitors

$17.11
-0.51 (-2.89%)
(As of 09/22/2023 08:52 PM ET)
Compare
Today's Range
$17.10
$17.62
50-Day Range
$17.11
$19.15
52-Week Range
$16.93
$27.20
Volume
363,900 shs
Average Volume
388,929 shs
Market Capitalization
$752.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.00

RGNX vs. ADPT, IBRX, ADMA, NVAX, ADAP, SANA, AMAM, CABA, AXLA, and VALN

Should you be buying REGENXBIO stock or one of its competitors? The main competitors of REGENXBIO include Adaptive Biotechnologies (ADPT), ImmunityBio (IBRX), ADMA Biologics (ADMA), Novavax (NVAX), Adaptimmune Therapeutics (ADAP), Sana Biotechnology (SANA), Ambrx Biopharma (AMAM), Cabaletta Bio (CABA), Axcella Health (AXLA), and Valneva (VALN). These companies are all part of the "biological products, except diagnostic" industry.

REGENXBIO vs.

REGENXBIO (NASDAQ:RGNX) and Adaptive Biotechnologies (NASDAQ:ADPT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, community ranking, earnings and media sentiment.

In the previous week, REGENXBIO had 2 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 4 mentions for REGENXBIO and 2 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.20 beat REGENXBIO's score of 1.13 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
REGENXBIO
3 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Adaptive Biotechnologies
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Adaptive Biotechnologies has a net margin of -100.69% compared to REGENXBIO's net margin of -282.72%. Adaptive Biotechnologies' return on equity of -43.10% beat REGENXBIO's return on equity.

Company Net Margins Return on Equity Return on Assets
REGENXBIO-282.72% -56.21% -34.84%
Adaptive Biotechnologies -100.69%-43.10%-23.16%

Adaptive Biotechnologies has higher revenue and earnings than REGENXBIO. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
REGENXBIO$112.72M6.67-$280.32M-$6.32-2.71
Adaptive Biotechnologies$189.60M3.87-$200.19M-$1.33-3.81

REGENXBIO has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500.

REGENXBIO currently has a consensus target price of $35.00, suggesting a potential upside of 104.56%. Adaptive Biotechnologies has a consensus target price of $12.25, suggesting a potential upside of 141.62%. Given Adaptive Biotechnologies' higher possible upside, analysts plainly believe Adaptive Biotechnologies is more favorable than REGENXBIO.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
REGENXBIO
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.60
Adaptive Biotechnologies
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

88.8% of REGENXBIO shares are held by institutional investors. Comparatively, 94.3% of Adaptive Biotechnologies shares are held by institutional investors. 13.6% of REGENXBIO shares are held by insiders. Comparatively, 5.2% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

REGENXBIO received 327 more outperform votes than Adaptive Biotechnologies when rated by MarketBeat users. Likewise, 66.61% of users gave REGENXBIO an outperform vote while only 55.84% of users gave Adaptive Biotechnologies an outperform vote.

CompanyUnderperformOutperform
REGENXBIOOutperform Votes
413
66.61%
Underperform Votes
207
33.39%
Adaptive BiotechnologiesOutperform Votes
86
55.84%
Underperform Votes
68
44.16%

Summary

Adaptive Biotechnologies beats REGENXBIO on 10 of the 18 factors compared between the two stocks.


Get REGENXBIO News Delivered to You Automatically

Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RGNX vs. The Competition

MetricREGENXBIOBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$752.16M$2.61B$4.29B$6.25B
Dividend YieldN/A2.25%5.83%9.75%
P/E Ratio-2.714.37102.9711.17
Price / Sales6.67150.312,890.4356.12
Price / CashN/A25.0928.2625.76
Price / Book1.443.403.844.79
Net Income-$280.32M$55.87M$119.85M$185.19M
7 Day Performance-3.93%25.63%110.53%3.51%
1 Month Performance-5.73%10.32%113.74%8.58%
1 Year Performance-25.15%17.69%129.84%4.85%

REGENXBIO Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ADPT
Adaptive Biotechnologies
2.1776 of 5 stars
$5.43
-1.6%
$12.25
+125.6%
-22.0%$785.42M$189.60M-4.08790Positive News
IBRX
ImmunityBio
1.6277 of 5 stars
$1.79
+7.2%
$4.00
+123.5%
-65.8%$816.69M$240,000.000.00683
ADMA
ADMA Biologics
2.2576 of 5 stars
$3.65
+0.3%
$6.00
+64.4%
+49.4%$820.92M$154.08M-18.25617
NVAX
Novavax
2.0748 of 5 stars
$7.68
+3.6%
$33.00
+329.7%
-66.0%$724.99M$1.98B-1.061,992
ADAP
Adaptimmune Therapeutics
1.5763 of 5 stars
$0.73
-1.4%
$5.10
+601.0%
-33.1%$723.29M$27.15M-1.37534
SANA
Sana Biotechnology
1.9053 of 5 stars
$4.39
+3.8%
$9.50
+116.4%
-35.4%$864.57MN/A-2.32476News Coverage
AMAM
Ambrx Biopharma
2.3191 of 5 stars
$11.33
+10.5%
$22.57
+99.2%
+969.5%$702.57M$7.40M0.0079Analyst Revision
CABA
Cabaletta Bio
2.138 of 5 stars
$17.36
-6.9%
$21.00
+21.0%
+2,414.3%$691.10MN/A-10.0377
AXLA
Axcella Health
1.6142 of 5 stars
$12.15
+1,925.0%
$131.25
+980.2%
-74.4%$895.33MN/A-15.7811Gap Up
VALN
Valneva
2.151 of 5 stars
$13.00
-4.4%
$22.00
+69.2%
+16.0%$902.98M$380.73M-5.28719Gap Down

Related Companies and Tools

This page (NASDAQ:RGNX) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -